|INSYS Therapeutics, Inc.|
1333 South Spectrum Boulevard
United States - Map
Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets Subsys, a proprietary sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients; and Dronabinol SG Capsule, a dronabinol soft gelatin capsule that is generic equivalent to Marinol, an approved second-line treatment for chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. Its products candidates also include Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol. The company is headquartered in Chandler, Arizona.
|INSYS Therapeutics, Inc.’s ISS Governance QuickScore as of Jul 1, 2015 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 10; Compensation: 9.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. John N. Kapoor Ph.D.,
Co-Founder and Exec. Chairman
|Mr. Michael L. Babich ,
Chief Exec. Officer, Pres and Director
|Mr. Darryl S. Baker ,
Chief Financial Officer
|Mr. Franc Del Fosse ,
Gen. Counsel and Corp. Sec.
| Venkat Goskonda Ph.D.,
Sr. Director of Pharmaceutical Devel.
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|